Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
Year: 2008
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Keywords: candesartan, diabetic retinopathy, type 2 diabetes, retinopathy progression, retinopathy regression, angiotensin receptor blockers, blindness prevention, blood pressure, adverse events, normoalbuminuria, hypertension, normotension, dose escalation, treatment discontinuation, retinopathy screening
Open Access status: green
Funder: AstraZeneca
OpenAlex ID: W2109689720
